Clinical Trials Logo

Human Immunodeficiency Virus clinical trials

View clinical trials related to Human Immunodeficiency Virus.

Filter by:

NCT ID: NCT00296153 Completed - Clinical trials for Ischemic Heart Disease

Omacor and Cardiovascular Risk Factors in HIV Patients on HAART Treatment

Start date: February 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the effect of Omacor 4g/day on blood lipid parameters and on the function and stiffness of blood vessels in HIV infected patients on Antiretroviral Therapy (HAART)

NCT ID: NCT00244803 Completed - Clinical trials for Human Immunodeficiency Virus

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

Start date: January 2005
Phase: N/A
Study type: Observational

The purpose of this study is to learn whether HIV-infected patients have blood abnormalities which could lead to heart attack or stroke, and to find out what factors may contribute to these abnormalities.

NCT ID: NCT00187148 Completed - HIV Infections Clinical Trials

Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults

Start date: February 2005
Phase: Phase 1
Study type: Interventional

This protocol will evaluate the safety and tolerability of the vaccine EnvDNA in healthy adults. DNA-based vaccines are being studied for the prevention of human immunodeficiency virus (HIV), malaria and hepatitis. DNA vaccines have been well tolerated in human studies to date. The vaccine that will be tested in this study was made from the information that the virus uses to make a small part of the HIV. This small part is called the envelope or coating around the virus. We hope the body will make an immune response against the HIV envelope coat. Our potential HIV DNA envelope vaccine is called EnvDNA.

NCT ID: NCT00187044 Completed - HIV Infection Clinical Trials

Evaluation of the Safety of a Polyvalent Virus in Healthy Adults

Start date: October 1997
Phase: Phase 1
Study type: Interventional

This is a research study to evaluate the safety of a vaccine to protect people from HIV infection. Human Immunodeficiency Virus (HIV) is the cause of AIDS (Acquired Immune Deficiency Syndrome). AIDS is one of the most serious viral infections of our time. It is believed that all persons who contract HIV will eventually develop AIDS. Because of this, we are trying to develop new ways to prevent infection with HIV. The vaccine that will be tested in this study has been prepared from a small part of the HIV. The part of the HIV used in this vaccine is the "envelope" or coating part of the virus. In this study, researchers will evaluate how well the vaccine is tolerated, how much vaccine should be given, and determine if any side effects occur in response to the vaccination.

NCT ID: NCT00064740 Completed - Clinical trials for Human Immunodeficiency Virus

Relaxation Response With Acupuncture for HIV Patients

Start date: July 2003
Phase: Phase 2
Study type: Interventional

Advances in treatment has turned HIV/AIDS into a chronic illness. Relaxation response is a state in which individuals evoke a bodily calm, effecting physiological changes that are shown to be associated with improved immune functioning. Acupuncture and relaxation are thought to both induce calm and deep relaxation in mind and body. This trial will study the combined effects of acupuncture and relaxation response in HIV patients.

NCT ID: NCT00051844 Completed - Clinical trials for Human Immunodeficiency Virus

Capravirine (AG1549) in Combination With Viracept and Two NRTIs in HIV Infected Patients Who Failed an Initial NNRTI Containing Regimen

Start date: August 2002
Phase: Phase 2
Study type: Interventional

This is a 48 week study that is intended for HIV Infected persons whose first treatment regimen was with a nonnucleoside reverse transcriptase inhibitor (NNRTI) and who are now failing that regimen. They must be currently on their failing regimen to be eligible.